Target family: Voltage-gated potassium channels (K<sub>v</sub>) (type: vgic)
Target: K<SUB>v</SUB>1.2

Ligand: α-dendrotoxin (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol

Ligand: α-dendrotoxin (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Identification of amino acid residues involved in dendrotoxin block of rat voltage-dependent potassium channels.
Published in: Mol Pharmacol

Ligand: α-KTx 13.2 (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity: 7 pKd
Reference (Journal): OsK2, a new selective inhibitor of Kv1.2 potassium channels purified from the venom of the scorpion Orthochirus scrobiculosus.
Published in: Biochem Biophys Res Commun

Ligand: anandamide (Metabolite)
Interaction type: Channel blocker
Action: Pore blocker
Ligand approved: no
Primary target: no
Median affinity: 5.599999904632568 pIC50
Reference (Journal): Anandamide, an endogenous cannabinoid, inhibits Shaker-related voltage-gated K+ channels.
Published in: Neuropharmacology

Ligand: BgK (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity: 7.6 pIC50
Reference (Journal): A potassium-channel toxin from the sea anemone Bunodosoma granulifera, an inhibitor for Kv1 channels. Revision of the amino acid sequence, disulfide-bridge assignment, chemical synthesis, and biological activity.
Published in: Eur J Biochem

Ligand: capsaicin (Natural product)
Interaction type: Channel blocker
Action: Pore blocker
Ligand approved: yes
Approval source: EMA & FDA (2009)
Primary target: no
Median affinity: 4.400000095367432 pKd
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol

Ligand: charybdotoxin (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity: 7.9 pKd
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol

Ligand: dendrotoxin-I (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity: 7.8 pKd
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol

Ligand: diltiazem (Synthetic organic)
Interaction type: Channel blocker
Action: Pore blocker
Ligand approved: yes
Approval source: FDA (1982)
Primary target: no
Median affinity: 3.700000047683716 pKd
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol

Ligand: fampridine (Synthetic organic)
Interaction type: Channel blocker
Action: Pore blocker
Ligand approved: yes
Approval source: FDA (2010), EMA (2011)
Primary target: no
Median affinity: 3.200000047683716 pKd
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol

Ligand: flecainide (Synthetic organic)
Interaction type: Channel blocker
Action: Pore blocker
Ligand approved: yes
Approval source: FDA (1985)
Primary target: no
Median affinity: 3.700000047683716 pKd
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol

Ligand: hongotoxin-1 (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  pKd
Reference (Journal): Subunit composition of brain voltage-gated potassium channels determined by hongotoxin-1, a novel peptide derived from Centruroides limbatus venom.
Published in: J Biol Chem

Ligand: κM-conotoxin RIIIK (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.46999979019165 pIC50
Reference (Journal): Identification of a mammalian target of kappaM-conotoxin RIIIK.
Published in: Toxicon

Ligand: κM-conotoxin RIIIK (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.550000190734863 pIC50
Reference (Journal): Identification of a mammalian target of kappaM-conotoxin RIIIK.
Published in: Toxicon

Ligand: margatoxin (Peptide)
Interaction type: Channel blocker
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 11.199999809265137 pIC50
Reference (Journal): Margatoxin is a non-selective inhibitor of human Kv1.3 K+ channels.
Published in: Toxicon

Ligand: mast cell degranulating peptide (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.400000095367432 pIC50
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol

Ligand: nifedipine (Synthetic organic)
Interaction type: Channel blocker
Action: Pore blocker
Ligand approved: yes
Approval source: FDA (1981)
Primary target: no
Median affinity: 4.699999809265137 pKd
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol

Ligand: noxiustoxin (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pKd
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol

Ligand: pandinotoxin-K α (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 10.5 pIC50
Reference (Journal): OsK2, a new selective inhibitor of Kv1.2 potassium channels purified from the venom of the scorpion Orthochirus scrobiculosus.
Published in: Biochem Biophys Res Commun

Ligand: resiniferatoxin (Natural product)
Interaction type: Channel blocker
Action: Pore blocker
Ligand approved: no
Primary target: no
Median affinity: 4.5 pKd
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol